Conjupro Biotherapeutics, Inc.

Subsidiary of CSPC Pharmaceutical Group (1093)

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
EGFRAntibody–drug conjugate
Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaBreast Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 August 2026Topline resultCPO301Phase 3 SYNSTAR01 (NCT06927986) of SYS6010 met its pre-specified PFS primary endpoint at interim analysis

Financial reports

No financial reports recorded.